Researchers at Weill Cornell Medicine and MIT have pinpointed a molecular switch — a gene-regulating factor called GATA6 — that controls whether colorectal cancer cells stay put or turn into aggressive, fetal-like cells capable of spreading to the liver. When GATA6 levels drop, cancer cells shed their normal identity and become highly adaptable metastatic agents. The discovery opens the door to new biomarkers and therapies targeting cancer spread at its earliest stages.
Researchers at Weill Cornell Medicine and MIT have uncovered a key molecular mechanism behind one of colorectal cancer's most dangerous traits: its ability to spread to the liver. The culprit isn't a new genetic mutation — it's the loss of a gene-regulating factor called GATA6, which normally acts as an "identity keeper" for intestinal cells. When GATA6 levels fall, cancer cells can abandon their specialized identity and shift into a flexible, fetal-like state that makes them far better at traveling through the bloodstream and colonizing distant organs.
The team used organoid models derived from liver metastases, implanting them into mouse colons to observe how cancer cells gradually acquire metastatic abilities. They found that GATA6 loss triggers a shift from LGR5-positive to LGR5-negative cells — a transition previously linked to liver metastasis initiation. Crucially, restoring GATA6 activity reduced metastatic potential, while deleting it significantly increased liver metastasis in mouse models without affecting primary tumor growth.
Key Takeaways:
Why it matters: Metastasis is the leading cause of death in colorectal cancer, yet no clear driver mutations had previously been identified. This research shifts the focus toward epigenetic cell-state transitions, potentially unlocking new strategies to detect high-risk patients earlier and block cancer spread before it starts.
